AIM

AEROSONIC CORP

AIM

Market cap $370M

Overview Fund Activity

Delisted

AIM was delisted on the 10th of June, 2013.

Back to rankings

Industrials Aerospace & Defense

Financial journalist opinion

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5 th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation now available here

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Tom Equels, CEO of AIM ImmunoTech provides a corporate update and reiterates focus on driving Ampligen forward in pancreatic cancer Tom Equels, CEO of AIM ImmunoTech provides a corporate update and reiterates focus on driving Ampligen forward in pancreatic cancer

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates promising signs of both no significant toxicity and superior PFS and OS Bolstered cash position provides runway to fund operations for approximately 12 months OCALA, Fla., Aug. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the second quarter 2025.

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

OCALA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025.

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

There will be presentations on the latest positive progress from AIM's clinical program in pancreatic cancer, the positive therapeutic effects of AIM's drug Ampligen on multiple cancer types, and Ampligen's mechanism of action in oncology

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Primary focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive signs of both no significant toxicity and superior PFS and OS Bolstered cash position provides runway to fund operations for approximately 12 months OCALA, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent key financial milestones and firmly stated its focus on advancing clinical trials of Ampligen® for the treatment of pancreatic cancer, with the ultimate goal of achieving drug approval.

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Why Is Micro-Cap AIM ImmunoTech Stock Surging?

Biotechnology firms are increasingly turning to innovative combination therapies to tackle hard-to-treat cancers, with promising results sparking investor interest. AIM ImmunoTech Inc. AIM is the latest to capture attention, as its stock soars following a promising mid-year update from the DURIPANC Phase 2 study.

Why Is Micro-Cap AIM ImmunoTech Stock Surging?

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

OCALA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a presentation and discussion on immunotherapies involving AIM's drug Ampligen at the recent U.S.-Poland Science and Technology Symposium 2025 , held June 17–20, 2025, across Silicon Valley, San Francisco and Stanford University. Pawel Kalinski, MD, PhD, a world-renowned research oncologist, presented on the drug and participated in a discussion session titled Revolution in Healthcare.

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

AIM ImmunoTech Resumes Trading on NYSE American

Company trading under the ticker “AIM” NYSE American effective at the start of trading today, Tuesday, June 17th Company trading under the ticker “AIM” NYSE American effective at the start of trading today, Tuesday, June 17th

AIM ImmunoTech Resumes Trading on NYSE American

See News Rankings

Charts implemented using Lightweight Charts™